We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Bioglan Vitamin K2 + D3 (Natural Bio Pty Limited)
Product Name
Bioglan Vitamin K2 + D3
Sponsor
ARTG details
- 393367
Date of review outcome
Date of publication
Jun-2025
Outcome
Medicine is no longer permitted to be supplied
Is it safe to continue using this medicine?
Yes, based on the sponsor’s certification. However, follow the recommended actions below.
What action should consumers take?
Consider whether this medicine is right for you given that the claim for helping to enhance or promote bone strength in individuals over 50 years was not substantiated by the sponsor.
Be aware that this medicine may also not work as expected in relation to enhancing bone strength and bone mineralisation in the general population, boosting calcium absorption into bones, and helping protect against osteoporosis.
Be aware that this medicine may also not work as expected in relation to enhancing bone strength and bone mineralisation in the general population, boosting calcium absorption into bones, and helping protect against osteoporosis.
Review scope
Targeted (see Additional Information below)
Information reviewed
ARTG Record, Evidence, Labels, Website
Issues related to safety
The safety of this medicine was not assessed as part of this review
Issues related to efficacy
The sponsor did not hold sufficient evidence to support the claim related to helping enhance or promote bone strength in individuals over 50 years. The limitations with the evidence included the study population, active ingredient, dosage, and the results of some studies not being relevant to this medicine. Some of the evidence provided was not of sufficient quality.
The website for this medicine claimed it could enhance bone strength and bone mineralisation in the general population, boost calcium absorption into bones, and help protect against osteoporosis. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
The website for this medicine claimed it could enhance bone strength and bone mineralisation in the general population, boost calcium absorption into bones, and help protect against osteoporosis. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor cancelled this medicine and withdrew it from further supply.
Additional information
This medicine was targeted to check its compliance in relation to claims about enhancing or promoting bone strength